Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03126786 · ClinicalTrials.gov registry record · Phase 2
Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
A Phase 2 study, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT03126786: Completed Phase 2 study, sponsored by Clearside Biomedical.
NCT03126786 is a Phase 2 study that has completed, run by Clearside Biomedical. The registered enrollment target is 71 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03126786, a Phase 2 study, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety and efficacy of suprachoroidal CLS-TA used with intravitreal aflibercept in subjects with DME.
Primary Outcome
Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.
Interventions
- DRUG SC CLS-TA
- DRUG IVT aflibercept
- DRUG Sham SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2018-04-17 |
| Phase | Phase 2 |
What the finished NCT03126786 record still lists
NCT03126786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which SC CLS-TA is the first listed.
NCT03126786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03126786 about?
NCT03126786 is a clinical study titled "Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema". The purpose of this trial is to evaluate the safety and efficacy of suprachoroidal CLS-TA used with intravitreal aflibercept in subjects with DME.
What is the current status of trial NCT03126786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2017-07-11. Estimated completion is 2018-04-17.
What interventions are being tested in trial NCT03126786?
The interventions under investigation include: SC CLS-TA (DRUG), IVT aflibercept (DRUG), Sham SC (DRUG).
Who is sponsoring clinical trial NCT03126786?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03126786's enrollment target sits among peer trials
71 936th of 2000 higher than 1,064 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI